René Crans
Research group
- Genetic predisposition to gastrointestinal cancer Post-doctoral researcher (R2A)
About me
With over 10 years of experience in biomedical and molecular biology, I am a passionate, data-driven Senior Scientist specialized in research across multiple disorders, including Colorectal Cancer, Alzheimer’s disease, Parkinson’s disease, and Down syndrome.
My expertise spans pharmacology, advanced molecular biology techniques (e.g., co-localization studies and in vitro assays), preclinical models, bioinformatic analyses (e.g., RNA-seq and Metabolomics), and the development of innovative 3D organoid models that capture disease-specific mechanisms.
In particular, I have contributed meaningful advancements toward potential therapeutic strategies in both disease models and human patient studies, resulting in 10 peer-reviewed publications, and 5 funded project grants.
Featured publications
-
Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease
Authors:Reference: Alzheimers & Dementia 2025. -
Striatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders (vol 11 pg 194, 2020)
Authors:Reference: Frontiers in Pharmacology 2022. -
Dopaminergic-cholinergic imbalance in movement disorders: a role for the novel striatal dopamine D2- muscarinic acetylcholine M1 receptor heteromer
Authors:Reference: Neural Regeneration Research 2021. -
Striatal Dopamine D2-Muscarinic Acetylcholine M1 Receptor-Receptor Interaction in a Model of Movement Disorders
Authors:Reference: Frontiers in Pharmacology 2020. -
Kainic acid-induced status epilepticus decreases mGlu5 receptor and phase-specifically downregulates Homer1b/c expression
Authors:Reference: BRAIN RESEARCH 2020. -
The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy
Authors:Reference: PLoS One 2019. -
Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A
Authors:Reference: Oncotarget 2017.